|
|||
|
Multiple Sclerosis Information
Search
This Month
Favorite Links
Month Archive
|
Monday, June 29
Autoinjection Device Appears subcutaneous injections of interferon beta (IFNB)-1a
by
All About MS
on Mon 29 Jun 2009 04:55 PM CST
A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European more »
Sunday, June 28
Cognitive function Improved by disease-modifying therapies
by
All About MS
on Sun 28 Jun 2009 10:30 AM CST
Patients with relapsing-remitting multiple sclerosis (RRMS) who receive glatiramer acetate (GA) or interferon (IFN) beta show a reduction in cognitive impairment and relative stability of cognitive and affective variables at 2 years, according to the results of an observational study presented more »
Friday, June 26
Richer Source for Stem Cells = Placentas?
by
All About MS
on Fri 26 Jun 2009 11:24 AM CST
The human placenta could be an important source of stem cells for curing leukemia, sickle cell disease and other blood-related disorders, a new study reveals. These stem cells appear to have distinct advantages over the techniques currently used to fight such diseases, and they more »
Sunday, June 21
Clinical Study – Volunteers Needed 2
by
All About MS
on Sun 21 Jun 2009 01:00 AM CST
This is an early phase study designed to test the safety of a compound. This is one of the steps necessary before conducting a large clinical trial to determine if the agent ONO-4641 is effective in MS.
Main Eligibility R more »
Saturday, June 20
Clinical Study – Volunteers Needed
by
All About MS
on Sat 20 Jun 2009 09:32 AM CST
A Randomized, Double-blind, Placebo-Controlled, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS-0777,
Administered more »
Friday, June 19
Clinical Trial - Spasticity
by
All About MS
on Fri 19 Jun 2009 08:27 AM CST
This research study will evaluate a treatment for moderate to severe spasticity associated with MS. All patients must have been on baclofen for at least four weeks prior to first visit. This study requires five visits over more »
Wednesday, June 17
Interracial Origins of MS
by
All About MS
on Wed 17 Jun 2009 01:00 AM CST
Multiple Sclerosis (MS) is a complex neurologic disease with a striking geographical distribution. In Canada, prevalence is high in Caucasians of Northern European ancestry and uncommon in North American Aboriginals, more »
Tuesday, June 16
Stem Cell Clinical Trials, Questions
by
All About MS
on Tue 16 Jun 2009 01:00 AM CST
Many readers have been wishing to know how they can be part of clinical trials for stem cell research. I have researched stem cell research trials for some time now. I cannot find even one clinical trial for stem cell research more »
Monday, June 15
Mitoxandrone - Leukemia Risk
by
All About MS
on Mon 15 Jun 2009 09:46 AM CST
Patients with multiple sclerosis who are treated with a cumulative dose of 82 mg/m[2 of Mitoxandrone (MTX) are at a 2.7 higher risk of developing acute leukemia (AL), according to a late-breaking abstract presented on April 30 more »
Sunday, June 14
Vision Deteriorates Without Sight-Related Symptoms
by
All About MS
on Sun 14 Jun 2009 11:14 AM CST
Researchers suggest that clinicians make a point of checking patients with multiple sclerosis (MS) for diminished vision even when the patients have not experienced any vision-related symptoms such as optic neuritis. The study was presented on May 3 at the more »
study - interferon beta-1a, azathioprine, & corticosteroids
by
All About MS
on Sun 14 Jun 2009 12:00 AM CST
Studies evaluating interferon beta (IFNbeta) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFNbeta does not halt relapses or disability progression. One strategy to potentially enhance efficacy is more »
Saturday, June 13
Fatigue Patients have Impaired Muscle Activation
by
All About MS
on Sat 13 Jun 2009 12:00 AM CST
To elucidate the role of central motor activation we hypothesized that patients with primary fatigue have impaired central motor function and increased fatigability as compared to secondary fatigued and non-fatigued more »
Friday, June 12
Remyelination of brain decreases with chronicity
by
All About MS
on Fri 12 Jun 2009 09:34 AM CST
To analyze and compare the extent of remyelination in lesions from patients with multiple sclerosis (MS) who have a short (early MS lesions) or a long (chronic MS lesions) disease duration and to determine the influence of more »
Causes Of MS - Tracking Them
by
All About MS
on Fri 12 Jun 2009 01:00 AM CST
Multiple sclerosis is a very complex disease of the nervous system. Thanks to the development of the new animal model, significantly improved insights into its emergence more »
Multiple sclerosis rehabilitation outcomes
by
All About MS
on Fri 12 Jun 2009 12:00 AM CST
De-identified data from the AROC database were analyzed for all rehabilitation admissions during 2003-2007, using four classes for functional level. The outcomes included Functional Independence Measure (FIM) scores and more »
|
||
